Publication: Monitoring of Risedronate by biochemical bone markers in clinical practice.
1
Issued Date
2005-10-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-34248592208
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Vol.88, No.suppl 5 (2005)
Suggested Citation
Narong Bunyaratavej Monitoring of Risedronate by biochemical bone markers in clinical practice.. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Vol.88, No.suppl 5 (2005). Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/16784
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Monitoring of Risedronate by biochemical bone markers in clinical practice.
Author(s)
Other Contributor(s)
Abstract
The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.